Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival

⋮

0

← $

..going to article 406

X Mark channel Not-Safe-For-Work? cancel confirm NSFW Votes: (0 votes)

X Are you the publisher? Claim or contact us about this channel.

X No ratings yet.

X Search